The pyrimidine analog FNC inhibits cell proliferation and viral protein synthesis in HTLV‑1‑infected cells

Jeang KT: HTLV-1 and adult T-cell leukemia: insights into viral transformation of cells 30 years after virus discovery. J Formos Med Assoc. 109:688–693. 2010.PubMed/NCBI

Taylor GP and Matsuoka M: Natural history of adult T-cell leukemia/lymphoma and approaches to therapy. Oncogene. 24:6047–6057. 2005. View Article : Google Scholar : PubMed/NCBI

Geleziunas R, Gallagher K, Zhang H, et al: HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2′,3′-dideoxy-2′,3′-didehydro-5-fluorocytidine (Reverset). Antivir Chem Chemother. 14:49–59. 2003.PubMed/NCBI

Wang Q, Liu X, Wang Q, et al: FNC, a novel nucleoside analogue inhibits cell proliferation and tumor growth in a variety of human cancer cells. Biochem Pharmacol. 81:848–855. 2011. View Article : Google Scholar : PubMed/NCBI

Klumpp K, Kalayanov G, Ma H, et al: 2′-deoxy-4′-azido nucleoside analogs are highly potent inhibitors of hepatitis C virus replication despite the lack of 2′-alpha-hydroxyl groups. J Biol Chem. 283:2167–2175. 2008.

Zheng L, Wang Q, Yang X, et al: Antiviral activity of FNC, 2′-deoxy-2′-β-fluoro-4′-azidocytidine, against human and duck HBV replication. Antivir Ther. 17:679–687. 2012.

Shvarzbeyn J and Huleihel M: Effect of propolis and caffeic acid phenethyl ester (CAPE) on NFκB activation by HTLV-1 Tax. Antiviral Res. 90:108–115. 2011.

Takeuchi K, Kobayashi N, Nam SH, Yamamoto N and Hatanaka M: Molecular cloning of cDNA encoding gp68 of adult T-cell leukaemia-associated antigen: evidence for expression of the pX IV region of human T-cell leukaemia virus. J Gen Virol. 66:1825–1829. 1985. View Article : Google Scholar

Miwa M, Shimotohno K, Hoshino H, Fujino M and Sugimura T: Detection of pX proteins in human T-cell leukemia virus (HTLV)-infected cells by using antibody against peptide deduced from sequences of X-IV DNA of HTLV-I and Xc DNA of HTLV-II proviruses. Gann. 75:752–755. 1984.

Amano M, Setoyama M, Grant A and Kerdel FA: Human T-lymphotropic virus 1 (HTLV-1) infection - dermatological implications. Int J Dermatol. 50:915–920. 2011. View Article : Google Scholar : PubMed/NCBI

Araya N, Takahashi K, Sato T, et al: Fucoidan therapy decreases the proviral load in patients with human T-lymphotropic virus type-1-associated neurological disease. Antivir Ther. 16:89–98. 2011. View Article : Google Scholar : PubMed/NCBI

Baran-Marszak F, Feuillard J, Najjar I, et al: Differential roles of STAT1alpha and STAT1beta in fludarabine-induced cell cycle arrest and apoptosis in human B cells. Blood. 104:2475–2483. 2004. View Article : Google Scholar : PubMed/NCBI

Ueno M, Katayama K, Yasoshima A, Nakayama H and Doi K: 5-Azacytidine (5AzC)-induced histopathological changes in the central nervous system of rat fetuses. Exp Toxicol Pathol. 54:91–96. 2002. View Article : Google Scholar : PubMed/NCBI

Matsuoka M and Jeang KT: Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer. 7:270–280. 2007. View Article : Google Scholar : PubMed/NCBI

Grassmann R, Aboud M and Jeang KT: Molecular mechanisms of cellular transformation by HTLV-1 Tax. Oncogene. 24:5976–5985. 2005. View Article : Google Scholar : PubMed/NCBI

Wang X, Miyake H, Okamoto M, et al: Inhibition of the tax-dependent human T-lymphotropic virus type I replication in persistently infected cells by the fluoroquinolone derivative k-37. Mol Pharmacol. 61:1359–1365. 2002. View Article : Google Scholar : PubMed/NCBI